Cargando…

Immune-based therapeutic approaches in COVID-19

Coronavirus disease 2019 (COVID-19) is a viral disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a member of the Coronaviridae family. On March 11, 2020 the World Health Organization (WHO) has named the newly emerged rapidly-spreading epidemic as a pandemic. Besides the...

Descripción completa

Detalles Bibliográficos
Autores principales: Moeinafshar, Aysan, Yazdanpanah, Niloufar, Rezaei, Nima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108029/
https://www.ncbi.nlm.nih.gov/pubmed/35594701
http://dx.doi.org/10.1016/j.biopha.2022.113107
_version_ 1784708615625506816
author Moeinafshar, Aysan
Yazdanpanah, Niloufar
Rezaei, Nima
author_facet Moeinafshar, Aysan
Yazdanpanah, Niloufar
Rezaei, Nima
author_sort Moeinafshar, Aysan
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a viral disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a member of the Coronaviridae family. On March 11, 2020 the World Health Organization (WHO) has named the newly emerged rapidly-spreading epidemic as a pandemic. Besides the risk-reduction measures such as physical and social distancing and vaccination, a wide range of treatment modalities have been developed; aiming to fight the disease. The immune system is known as a double-edged sword in COVID-19 pathogenesis, with respect to its role in eliminating the pathogen and in inducing complications such as cytokine storm syndrome. Hence, immune-based therapeutic approaches have become an interesting field of COVID-19 research, including corticosteroids, intravenous immunoglobulins (IVIG), interferon therapy, and more COVID-19-specific approaches such as anti-SARS-CoV-2-monoclonal antibodies. Herein, we did a comprehensive review on immune-based therapeutic approaches for COVID-19. DATA AVAILABILITY STATEMENT: Not applicable.
format Online
Article
Text
id pubmed-9108029
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-91080292022-05-16 Immune-based therapeutic approaches in COVID-19 Moeinafshar, Aysan Yazdanpanah, Niloufar Rezaei, Nima Biomed Pharmacother Review Coronavirus disease 2019 (COVID-19) is a viral disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a member of the Coronaviridae family. On March 11, 2020 the World Health Organization (WHO) has named the newly emerged rapidly-spreading epidemic as a pandemic. Besides the risk-reduction measures such as physical and social distancing and vaccination, a wide range of treatment modalities have been developed; aiming to fight the disease. The immune system is known as a double-edged sword in COVID-19 pathogenesis, with respect to its role in eliminating the pathogen and in inducing complications such as cytokine storm syndrome. Hence, immune-based therapeutic approaches have become an interesting field of COVID-19 research, including corticosteroids, intravenous immunoglobulins (IVIG), interferon therapy, and more COVID-19-specific approaches such as anti-SARS-CoV-2-monoclonal antibodies. Herein, we did a comprehensive review on immune-based therapeutic approaches for COVID-19. DATA AVAILABILITY STATEMENT: Not applicable. The Authors. Published by Elsevier Masson SAS. 2022-07 2022-05-16 /pmc/articles/PMC9108029/ /pubmed/35594701 http://dx.doi.org/10.1016/j.biopha.2022.113107 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Moeinafshar, Aysan
Yazdanpanah, Niloufar
Rezaei, Nima
Immune-based therapeutic approaches in COVID-19
title Immune-based therapeutic approaches in COVID-19
title_full Immune-based therapeutic approaches in COVID-19
title_fullStr Immune-based therapeutic approaches in COVID-19
title_full_unstemmed Immune-based therapeutic approaches in COVID-19
title_short Immune-based therapeutic approaches in COVID-19
title_sort immune-based therapeutic approaches in covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108029/
https://www.ncbi.nlm.nih.gov/pubmed/35594701
http://dx.doi.org/10.1016/j.biopha.2022.113107
work_keys_str_mv AT moeinafsharaysan immunebasedtherapeuticapproachesincovid19
AT yazdanpanahniloufar immunebasedtherapeuticapproachesincovid19
AT rezaeinima immunebasedtherapeuticapproachesincovid19